Wells Fargo Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18

Benzinga · 3d ago
Wells Fargo analyst Yanan Zhu maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $14 to $18.